Les interactions lipides/hémostase: Une nouvelle approche des facteurs de risque cardio-vasculaire

Presse Medicale

Volumn 27, Issue 28, 1998, Pages 1437-1439

  Chadarevian, R ^a   Bruckert, E ^a   Turpin, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; LIPID;

BLOOD; CARDIOVASCULAR DISEASE; EDITORIAL; HEMOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY; RISK FACTOR; CARDIOVASCULAR RISK; LIPID BLOOD LEVEL; REVIEW;

BLOOD COAGULATION FACTORS; CARDIOVASCULAR DISEASES; HEMOSTASIS; HUMANS; LIPIDS; RISK FACTORS;

EID: 0032569282     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Meade TW, Mellows S, Brozovic et al. Haemostatic function and ischaemic heart disease : principal results of the Northwick Park Heart Study. Lancet 1986 ; Ü1533-7.
2. Wman B. Pbsminogen Activator Inhibitor 1 (RAM ) in plasma: te role in thrombotic disease. Ttiromb Hoemost 1995:74:71-6.
3. Lowe CDO, Rumley A, Yamell JWG et d. Fibrin D-dimer, von Willebrand factor, tissue plasminogen activator antigen, and plasminogen activator inhibitor activity are primary risk factors for ischaemic heart disease: the Caerphilly Study. Thromb Haemost 1995 ; 73:950.
4. Tofler GH, Brezinski D, Schafer AI el al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engt J Med 19B7 ; 316:1514-18.
5. Lee AJ, Lowe GDO, Woodward M et al. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: The Scottish Heart Health Study. Br Heart J 1993 ; 69:338-42.
6. Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Croup. N Engl J Med 1995 ;332:635-41.
7. Ernst E, Resch KL Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the litterature. Ann Intern Med 1993 ; 118:956-63.
8. Ericsson CG, Hamsten A, Nilsson J ef aJ. Angiographie assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Lancet 1996 ; 347:849-53.
9. Bradley WA, Booyse FM, Cianturco SH. Fibrinolytic and thrombotic factors in atherosclerosis and IHD: the influence of triglyceride rich lipoproteins (TCRLP). Atherosclerosis 1994 ; I08(suppl):S31-9.
10. Lacoste L, Lam JYT, Hung J ef al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172-7.